Results 91 to 100 of about 8,055 (251)
British Journal of Pharmacology, EarlyView.Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley +1 more source
Journal of Lipid and AtherosclerosisTirzepatide is the first dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GLP-1) receptor agonist to be approved for the treatment of diabetes mellitus.
Sakiko Terui +3 more
doaj +1 more source
Cardiometabolic Outcomes of Novel Therapy Tirzepatide: A Systematic Review
Description: This systematic review evaluates the efficacy and safety of tirzepatide in improving cardiometabolic outcomes, beyond its glycemic and weight loss effects, in patients with type 2 diabetes and obesity.
Osaghae, Osadebamwen +3 more
core +1 more source
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
British Journal of Pharmacology, EarlyView.Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley +1 more source
Tirzepatide: The Most Effective Drug Therapy for Prevention of Type 2 Diabetes [PDF]
Obesity is a main trigger for development of type 2 diabetes. Tirzepatide is a dual receptor agonist of glucagon-like 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and is a potent agent for controlling glycemic control and reducing ...
Nasser Mikhail
core +1 more source
Amylin analogues as a novel perspective in anti‐obesity therapy
British Journal of Pharmacology, EarlyView.Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley +1 more source
Gut microbiota as a novel therapeutic target for eating disorders and obesity
British Journal of Pharmacology, EarlyView.The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė +5 more
wiley +1 more source
Case Reports in NeurologyIntroduction: Common peroneal nerve palsy, termed “Slimmer’s Palsy,” is a recognized complication of rapid weight loss. This case report describes two patients who developed foot drop following tirzepatide-induced weight loss precipitated by ...
Ann I. Tanyous, Jacob Oren Levitt
doaj +1 more source
Assessment of eating behaviour changes in tirzepatide-treated patients: A questionnaire-based study.
reservedObesity represents a significant global public health challenge, closely linked to chronic diseases such as type 2 diabetes, cardiovascular issues, and certain types of cancer.
ENDRIZZI, GIORGIA
core
Peripheral targets for neuropathic pain
British Journal of Pharmacology, EarlyView.Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour +3 more
wiley +1 more source